Top Global Trend Areas of Scientific advancements in Life Science and Healthcare How Middle Eastern Healthcare Ecosystem can Benefit for these Advancement

1. Top 4 Global Trends in Life
Science & Healthcare
and why is this important
for Middle East.

2. ADVANCEMENTS IN GENOMIC MEDICINE …
$900B
2019
$1.2T
2024
GLOBAL PRESCRIPTION
DRUG SALES
$151B
2019
$262B
2024
ORPHAN CELL & GENE
THERAPIES GLOBAL SALES
+73%
5-yr Growth
+33%
5-yr Growth
… result in a growth rate for the sector, that is more than
double the pace of traditional prescription drugs (73% vs 33%)
Sources: Evaluate Pharma

3. There is a sector in Healthcare that is
experiencing a…
55%
Annual Growth Rate

4. MASSIVE GLOBAL TRENDS IN THE LIFE SCIENCE & HEALTHCARE SPACE
Worldwide spending on AI & cognitive computing technologies in Healthcare will climb to $46
billion by 2020 with 55%+ growth annual rate
The Chimeric Antigen Receptor T-cell (CAR-T) therapy market is projected to increase at an
annualized rate of over 51%+ during the time period, 2019–2030. More than 300 CAR-T
therapies are in research phase in US and 200 in China
US and China are in a race for "biointelligence," investing over US$9 billion (the later) in expanding
AI and biotech capabilities to commodify biological and genomic data
Google Ventures (GV), allocates a third of its funding to 60 health care and life sciences companies
from genetics to telemedicine
And investors are following closely the opportunities…
Immunotherapies are experiencing unprecedented growth…
AI is a key driver of growth in Healthcare…
The global powers are competing in a new frontier…
Sources: CAR-T Therapies Market, 2018-2030, Market Watch, Medtech Dive, US FDA

5. DISRUPTION IN MED TECH SECTOR … IS CREATING INVESTMENT OPPORTUNITIES
1. Regulation
Enabling Change
US FDA | EU MDR
Value-based pricing required by FDA. Medical device companies should invest in
technology that allows them to clearly link data with the device, consistently define
outcomes which then evaluated by FDA for reimbursement
MOH KSA
Implementation of population health management in KSA will increase the advent of MD
and tools that enable connection of the entire continuum of care (primary, secondary,
tertiary, long term) with emphasis Big Data, IoMT and Data Integrity
DRIVERS ANALYSIS
INVESTMENT
OPPORTUNITIES
Internet of Medical Things
(IoMT)
AI Telemedicine solcution
AI & Machine Learning in
Medical Devices
AI for treatment selection
AI Imaging & Diagnostic
2. University R&D
Enabling Change
Biohybrid kidney – will minimize the need for certain services (e.g. dialysis) a zero percent
chance of organ rejection. Researchers at the University of California have developed a
first prototype
Regenerative Medicine
Cell & Gene Therapies
Genetic Engineering
2. Private Companies’ R&D
Efforts Enabling Change
Google is working on using deep learning in imaging, to recognize patterns in a huge
number of digital images in order to detect signs of cancer in breast cancer biopsies
Novartis has partnered with Qualcomm Life to develop an internet-connected inhaler that
can send information to a cloud-based big data analytics platform which healthcare
providers can use to treat patients with chronic obstructive pulmonary disease
Medtronic in partnership with IBM Watson, has developed a diabetes management app
Automakers with strong expertise in AI and ML are moving in the Medical Device space
Software as a Medical
Device (SaaMD)
AI diagnostic devices
Deep Learning to Identify
NCD patients,
AI augmented reality
assisted surgery,
Hospital Decision Support
Software,
Time Discharge Software,
Sources: Medtech Dive, US FDA, Nature, MedCity News

6. Cell & Gene Therapies
Genetic Engineering
Genome Editing
Cancer Immunotherapy
TOP 4 GLOBAL AREAS OF SCIENTIFIC BREAKTHROUGHS
MedTech
Digital
Health &
Informatics
$
Life Science
(Biotech)
Machine
Learning & AI
Healthcare
SaaMD
IoMT – FDA requirement
Imaging & Diagnostics
Regenerative Medicine – Hybrid Kidney
IoMT
CDS SW
Tele Health
Wearables
AI diagnostic devices/SW (Imaging), AI for treatment
selection, Deep Learning Identifying NCD patients,
ML pre operation check list, AI augmented reality
assisted surgery, Hospital Decision Support Software,
Time Discharge Software, AI based telemedicine,
pervasive tech on surgical device, Time Driven
Activity Based Costing

7. WHY NOVEL THERAPIES IS THE FUTURE?
Governments seek treatments with high efficacy
(personalized & genomic medicine address this need)
1st Fact
 Transition from symptom treatment  medicines that cure ailments
 Transition from volume based contracting  value based contracting
 Specialty medicines will exceed 50% of pharmaceutical spending
Few therapies have been approved for rare ailments … thus
advancements in this space are high priority among researchers
2nd Fact
 From the 7,000 identified rare diseases (we estimate that 14,000
rare ailments are not yet discovered) only 5% have an FDA approved
therapy.
Sources: US FDA, PhRMA, Managed Care Mag

8. How Middle East can benefit from
global advancements in
Precision/Genomic Medicine?

9. Prevalent Diseases in ME*
• Sickle Cell Disease
• Alpha & Beta Thalassemia
• Spinal Muscular Atrophy
• Cystic Fibrosis
• Metabolic disorders
• G6PD deficiency
… TO HELP CURE GENETIC & RARE DISEASE, PREVALENT IN THE ARAB WORLD
*Sources: The Cancer Genome Atlas Project (TCGA Database) and research
Ziyad S. Almalki, Abdullah K. Alahmari, Jeff J. Guo, Christina M.L. Kelton - University of Cincinnati Academic Health Center
With a combined population of less than 400 million, about 2.8 million patients are estimated to be suffering from a rare
disease in the Middle East
Several groups of genetic disorders have reached epidemic
values and occur at extremely high annual incidences of >
100 cases/100,000 live births among Arab individuals. This
group encompasses all hemoglobinopathies
(thalassemias, sickle cell disease, and hemoglobin
variants), G6PD deficiency, Down syndrome, cancers
(breast, ovarian, cervical, lung), intestinal carcinoid

10. Few Questions to consider:
• What government and private sector can do regionally to
utilize some of these advancements?
• How local pharma companies can invest more to
commercialize specialty medicine?
• Is emphasis in generic medicine the right strategy moving
forward for regional pharma?
• How can we include more genomic medicine in regional
academic institutions educational agenda?
• Can we really create a cluster of precision medicine in Middle
East to address local hereditary diseases?